Aricept. Buy more. Save more.

Relatively simple adjustments in lighting may ease some of the behavioral problems associated with dementia, new research suggests.
Use of melatonin, a hormone which seems to play a role in the sleep-wake cycle, also helped patients…

Sept. 25, 2008 — Treating Alzheimer’s patients
with a combination of the two types of drugs now approved for the disease is
better than no treatment for delaying the progression of symptoms.
That i…

The drive to self-improvement is one of the defining aspects of
our culture. We are willing to go to great lengths to match our ideals; and if
you’re not an Adonis or Venus, a mental equal to Einstein, or the spiritual
equivalent of a saint, you may have felt a twinge of shame and pressure to wh…

Eisai Co., Ltd. (Headquarters: Tokyo,
President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey,
Chairman and CEO: Hajime Shimizu) today announce that they have filed a
lawsuit against Mutual Pharmaceutical Co., Ltd. and United Research
Laboratories, Inc. regarding its submission of an abbreviated new drug
application (ANDA) to the FDA for Aricept ODT Orally Disintegrating
Tablets (Active Ingredient Name: donepezil hydrochloride…

In early 1997, the pharmaceutical firm Eisai, Inc., Teaneck, began selling its first major drug - Aricept(R) - for the treatment of mild-tomoderate Alzheimer’s disease. The company, a subsidiary of Eisai Co., Ltd. of Japan, has been growing rapidly along the way, holding the distinction of becoming the fourth fastest company in any industry to pass the $1 billion mark in sales. Besides Aricept (which is copromoted with Pfizer), Eisai, Inc.’s…

Treatment with Aricept (donepezil) significantly improved memory, thinking and global function in patients with vascular dementia compared with placebo, according to an article published in this month’s issue of the peer-reviewed journal Neurology.

Related Results

Health: A ricept isn’t a cure, but it has made me a …

MODE OF ACTION

Reversible Cholinesterase Inhibitor

Preferential inhibition of acetyicholinesterase in the central nervous system.

Increases concentration of acetylcholine by preventing its hydrolysis by cholinesterase.

Result is im…

Eisai Co., Ltd. (Tokyo, Japan) and its United States subsidiary Eisai Inc. (Woodcliff Lake, NJ) announced that the United States District Court for the District of New Jersey has ruled in Eisai’s favor with respect to Eisai’s motion for a preliminary injunction in its patent infringement lawsuit agains…

Tokyo, Dec 21, 2005 - (JCN) - Eisai has announced that its US subsidiary Eisai Medical Research resubmitted a supplemental new drug application (sNDA) for Aricept, the company’s proprietary agent for treating severe Alzheimer’s disease, to the US Food and Drug Administration (FDA) as of December 16.

…

Eisai has taken on the U.S. distribution responsibilities for its Aricept (donepezil hydrochloride tablets) for treatment of mild to moderate Alzheimer’s disease. Formerly the domain of Pfizer, Eisai’s co-marketing partner, the U.S. distribution has been acquired by Eisai in an effort to “achieve independence and growth in the manufacturing, distribution and promotion of its own products …,” according to a company announcement.
The company also stated that it will continue to fost…